P25035 Pre-Assessment – Medical Learning Institute Inc

MedHive Pre-Assessment

Name

First

Last

NPI Number

To find your 10-digit NPI number, click here.

Location

Which of the following best represents your profession?

MD/DO
NP
PA
Other

If other, please specify

What is your primary speciality?

Endocrinology
Other

If other, please specify

1. A patient with T2D and CKD has persistent moderate-to-severe albuminuria despite optimized RASi and SGLT2i therapy. According to the 2025 ADA SOC, which parameter is most important for guiding escalation of kidney-protective therapy?

a) Blood pressure
b) Estimated glomerular filtration rate (eGFR)
c) Serum potassium
d) Urine albumin-to-creatinine ratio (UACR)

1b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

2. A 62-year-old patient with newly diagnosed T2D presents with A1C 9.2%, BMI 35 kg/m², ASCVD (prior MI), stage 3 CKD (eGFR 45 mL/min/1.73 m²), HFpEF, and limited insurance coverage. The patient wants avoid injections. Which initial therapy would you recommend?

a) DPP-4 inhibitor for simplicity
b) Metformin monotherapy for cost
c) SGLT2 inhibitor for HF benefit
d) Sulfonylurea for rapid glycemic reduction

2b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

3.Which clinical strategy helps you differentiate treatment efficacy from patient adherence?

a) Confirm adherence based on patient verbal affirmation during standard office visits
b) Integrate CGM data with EMR prompts to facilitate dedicated virtual or in-person visits
c) Monitor annual A1C monitoring supplemented by basic self-reported logs
d) Review pharmacy refill history regularly until evident disease progression

3b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

4. You are counseling a 58-year old patient with T2D, CVD, and A1C 7.8%. The patient is taking metformin +SGLT2i. To assess adherence, which question aligns with 2025 ADA Standards of Care?

a) Are you taking your diabetes medications exactly as prescribed?
b) Have you experienced any side effects or challenges with your current medications?
c) Why do you think your blood sugar is still too high?
d) Would you prefer to switch to a less expensive medication option?

4b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

5. Consider a 76-year-old female with longstanding T2D on metformin/sulfonylurea has A1C 8.2%, established CVD, BMI 32 kg/m², and frailty concerns typical in elderly patients. Which intensification strategy would you choose?

a) Add dual GIP/GLP-1 RA
b) Continue sulfonylurea escalation
c) Delay intensification due to age and polypharmacy concerns
d) Switch to pioglitazone for insulin sensitization

5b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

6. For an adherent patient with T2D on basal insulin at 0.6 U/kg/day, A1C 8.4%, and frequent postprandial hyperglycemia on CGM, which therapeutic adjustment would you make?

a) Add prandial insulin boluses empirically
b) Add weekly GLP-1 RA
c) Incorporate meglitinide for targeted postprandial hyperglycemia
d) Increase basal insulin > 0.6 U/kg/day

differentiate your BMI

6b. Please select the extent to which you feel confident in your answer

A. Completely confident	B. Fairly confident	C. Somewhat confident	D. Slightly confident	E. Not confident
A. Completely confidentA. Completely confident	B. Fairly confidentB. Fairly confident	C. Somewhat confidentC. Somewhat confident	D. Slightly confidentD. Slightly confident	E. Not confidentE. Not confident

7. How confident are you in your ability to incorporate ADA’s current standards of care for patients with T2D?